查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566971

結膜炎市場：按類型、疾病類型、最終用戶分類：2024-2033 年全球機會分析與產業預測

Conjunctivitis Market By Type , By Disease Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 228 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年結膜炎市值為48億美元，預計2024年至2033年複合年成長率為4.1%，到2033年達到72億美元。

結膜炎是最常見的眼部感染疾病，會導致結膜（排列在眼白和眼瞼內側的薄而透明的膜）發炎。它可能由多種因素引起，包括病毒和細菌感染、過敏原和刺激物。這種情況的特徵是眼睛發紅、發癢、腫脹和分泌物。結膜炎通常令人不舒服且具有傳染性，但通常是可以治療的，並且很少引起嚴重的併發症。

全球結膜炎市場的成長是由結膜炎的高盛行率（特別是在結膜炎頻繁發生的地區）以及對治療和預防措施的需求不斷增加所推動的。提供醫療新聞、臨床試驗報告和藥物更新的網站 Medscape 於 2024 年發表的一項研究估計，美國每年將出現 600 萬例新發病毒性結膜炎病例。由於污染和花粉等環境因素導致的過敏性結膜炎病例不斷增加，推動了對相關治療的需求。此外，病毒和細菌感染經常發生，特別是在學校和公共運輸等擁擠的環境中，增加了對有效治療方案的需求。此外，由於消費者意識的提高以及無需處方箋即可獲得這些產品的便利性，人們對非處方眼部護理產品的偏好增加，也對市場成長做出了重大貢獻。此外，老年人口的快速成長也推動了市場的成長。這是因為包括結膜在內的眼組織會自然退化。這使得老年人的眼睛更容易受到刺激、感染和發炎，從而更容易患上結膜炎等疾病。個人化醫療的趨勢正在進一步影響結膜炎市場，根據個別患者的情況和結膜炎的具體原因促進客製化治療。然而，許多人自我診斷結膜炎並使用非處方產品或家用藥物進行自我治療，這可能導致治療不正確和症狀惡化。誤診還會導致不當用藥，這是全球市場的一個主要阻礙因素。此外，獲得醫療服務和眼科醫生的機會有限，阻礙了結膜炎的及時診斷和治療，導致併發症發生率更高，從而限制了市場成長。相反，藥物研究的進步正在導致針對結膜炎的新的、更有效的治療方法的開發，包括新的抗生素和發炎治療。此外，將人工智慧和機器學習整合到診斷工具中，以提高結膜炎診斷和治療計劃的準確性和速度，預計將為市場成長提供新的途徑。

全球結膜炎市場按類型、疾病類型、最終用戶和地區細分。按類型分類，市場分為診斷市場和治療市場。診斷部分進一步細分為身體檢查和臨床檢查。治療部分進一步分為抗生素、抗病毒藥物、抗過敏藥物和人工淚液。根據疾病類型，市場分為過敏性結膜炎、細菌性結膜炎和病毒性結膜炎。過敏性結膜炎又分為季節性過敏性結膜炎和常年性過敏性結膜炎。依最終用戶分類，可分為醫院和診所、專業眼科診所和其他。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按類型分類，治療細分市場在 2023 年佔據最大佔有率。

按疾病類型分類，過敏性結膜炎細分市場在 2023 年佔據主導地位。

從最終用戶來看，醫院和診所將在 2023 年成為主要細分市場。

按地區分類，北美是 2023 年結膜炎市場的主要股東，預計在整個預測期內將保持主導地位。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第 4 章 聯合火焰市場：依類型

  • 市場概況
  • 診斷
    • 體檢
    • 臨床試驗
  • 治療
    • 抗生素
    • 抗病毒藥物
    • 抗過敏劑
    • 人工淚液

第5章綜合發炎市場：依疾病類型

  • 市場概況
  • 過敏性結膜炎
    • 季節性過敏性結膜炎
    • 常年性過敏性結膜炎
  • 細菌性結膜炎
  • 病毒性結膜炎

第6章結膜炎市場：依最終用戶分類

  • 市場概況
  • 醫院和診所
  • 專業眼科診所
  • 其他

第7章思覺失調症發炎市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國結膜炎市場
    • 加拿大結膜炎市場
    • 墨西哥結膜炎市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國結膜炎市場
    • 法國結膜炎市場
    • 英國結膜炎市場
    • 義大利結膜炎市場
    • 西班牙結膜炎市場
    • 其他歐洲結膜炎市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本結膜炎市場
    • 中國結膜炎市場
    • 印度結膜炎市場
    • 澳洲結膜炎市場
    • 韓國結膜炎市場
    • 其他亞太結膜炎市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西結膜炎市場
    • 沙烏地結膜炎市場
    • 南非結膜炎市場
    • 其他拉丁美洲/中東/非洲結膜炎市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • AFT Pharmaceuticals
  • Alembic Pharmaceuticals Ltd
  • Johnson And Johnson Services Inc
  • Ocular Therapeutics, Inc
  • Cipla, Inc.
  • Jabs Biotech Pvt. Ltd.
  • Spectra Vision Care Pvt. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Grevis Pharmaceutical Private Limited
  • Bausch Health Companies Inc
簡介目錄
Product Code: A324393

The conjunctivitis market was valued at $4.8 billion in 2023, and is projected to reach $7.2 billion by 2033, growing at a CAGR of 4.1% from 2024 to 2033.

Conjunctivitis is the most prevalent eye infection that causes the inflammation of the conjunctiva-the thin, transparent membrane that lines the white part of the eye and the inner surface of the eyelids. It can be caused by various factors, including viral or bacterial infections, allergens, or irritants. This condition is characterized by symptoms such as redness, itching, swelling, and discharge from the eye. While often uncomfortable and contagious, conjunctivitis is typically treatable and rarely causes serious complications.

The growth of the global conjunctivitis market is driven by high prevalence of conjunctivitis, particularly in regions with frequent outbreaks, drives demand for treatment and preventive measures. According to a 2024 study published by Medscape-website providing access to medical news, clinical trial coverage, drug updates-an estimated 6 million new cases of viral conjunctivitis occur annually in the U.S. Increase in cases of allergic conjunctivitis due to environmental factors, such as pollution and pollen, boosts the demand for relevant therapies. Moreover, frequent outbreaks of viral or bacterial infections, especially in crowded settings like schools and public transport, foster the need for effective treatment options. Furthermore, increase in preference for over-the-counter eye care products, driven by increased consumer awareness and the convenience of accessing these products without prescription, notably contributes toward the market growth. In addition, surge in geriatric population propels the market growth. This is attributed to the fact that the tissues in the eyes, including the conjunctiva, undergoes natural degeneration. This makes the eyes of aged individuals more prone to irritation, infections, and inflammation, leading to a higher likelihood of developing conditions like conjunctivitis, which augments the demand for specialized treatments. The trend toward personalized medicine is further impacting the conjunctivitis market by promoting tailored treatments based on individual patient profiles and specific conjunctivitis causes. However, many individuals self-diagnose and self-treat conjunctivitis with over-the-counter products or home remedies, which can lead to incorrect treatment and potential worsening of the condition. Misdiagnosis can also result in inappropriate use of medications, which acts as the key deterrent factor of the global market. In addition, limited access to healthcare services and eye care professionals hinders timely diagnosis and treatment of conjunctivitis, leading to higher rates of complications, thus restraining the market growth. On the contrary, advances in pharmaceutical research are leading to the development of new and more effective therapies, including novel antimicrobial agents and anti-inflammatory treatments for conjunctivitis. Furthermore, integration of AI and ML in diagnostic tools to improve the accuracy and speed of conjunctivitis diagnosis and treatment planning is anticipated to offer new avenues for the market growth.

The global conjunctivitis market is segmented into type, disease type, end user, and region. On the basis of the type, the market is bifurcated into diagnosis and treatment. The diagnosis segment is further segmented into physical examination and laboratory tests. The treatment segment is further classified into antibiotics, antiviral, anti-allergic, and artificial tears. Depending on disease type, the market is divided into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment is further categorized into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. As per end user, the market is classified into hospitals & clinics, specialty eye clinics, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the treatment segment accounted for the largest share of the market in 2023.

On the basis of disease type, the allergic conjunctivitis segment dominated the market in 2023.

Depending on end user, hospital & clinics emerged as the leading segment in 2023.

Region wise, North America was the major shareholder in the conjunctivitis market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global conjunctivitis market include AFT Pharmaceuticals, Alembic Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Ocular Therapeutics, Inc., Cipla, Inc., Jabs Biotech Pvt. Ltd., Spectra Vision Care Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Grevis Pharmaceutical Private Limited, and Bausch Health Companies Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Diagnosis
    • Physical Examination
    • Laboratory Tests
  • Treatment
    • Antibiotics
    • Antiviral
    • Anti-allergic
    • Artificial Tears

By Disease Type

  • Allergic Conjunctivitis
    • Seasonal Allergic Conjunctivitis
    • Perennial Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis

By End User

  • Hospitals and Clinics
  • Specialty Eye Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • AFT Pharmaceuticals
    • Alembic Pharmaceuticals Ltd
    • Johnson & Johnson Services Inc
    • Ocular Therapeutics, Inc
    • Cipla, Inc.
    • Jabs Biotech Pvt. Ltd.
    • Spectra Vision Care Pvt. Ltd
    • Teva Pharmaceutical Industries Ltd
    • Grevis Pharmaceutical Private Limited
    • Bausch Health Companies Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CONJUNCTIVITIS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Diagnosis
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
    • 4.2.5. Physical Examination
      • 4.2.5.1. Market Size and Forecast
    • 4.2.6. Laboratory Tests
      • 4.2.6.1. Market Size and Forecast
  • 4.3. Treatment
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
    • 4.3.5. Antibiotics
      • 4.3.5.1. Market Size and Forecast
    • 4.3.6. Antiviral
      • 4.3.6.1. Market Size and Forecast
    • 4.3.7. Anti-allergic
      • 4.3.7.1. Market Size and Forecast
    • 4.3.8. Artificial Tears
      • 4.3.8.1. Market Size and Forecast

CHAPTER 5: CONJUNCTIVITIS MARKET, BY DISEASE TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Disease Type
  • 5.2. Allergic Conjunctivitis
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.5. Seasonal Allergic Conjunctivitis
      • 5.2.5.1. Market Size and Forecast
    • 5.2.6. Perennial Allergic Conjunctivitis
      • 5.2.6.1. Market Size and Forecast
  • 5.3. Bacterial Conjunctivitis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Viral Conjunctivitis
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: CONJUNCTIVITIS MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Specialty Eye Clinics
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CONJUNCTIVITIS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Disease Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Conjunctivitis Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Disease Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Conjunctivitis Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Disease Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Conjunctivitis Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Disease Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Disease Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Conjunctivitis Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Disease Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Conjunctivitis Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Disease Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Conjunctivitis Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Disease Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Conjunctivitis Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Disease Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Conjunctivitis Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Disease Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Conjunctivitis Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Disease Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Disease Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Conjunctivitis Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Disease Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Conjunctivitis Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Disease Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Conjunctivitis Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Disease Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Conjunctivitis Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Disease Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Conjunctivitis Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Disease Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Conjunctivitis Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Disease Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Disease Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Conjunctivitis Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Disease Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Conjunctivitis Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Disease Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Conjunctivitis Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Disease Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Conjunctivitis Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Disease Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. AFT Pharmaceuticals
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Alembic Pharmaceuticals Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Johnson And Johnson Services Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Ocular Therapeutics, Inc
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Cipla, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Jabs Biotech Pvt. Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Spectra Vision Care Pvt. Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Teva Pharmaceutical Industries Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Grevis Pharmaceutical Private Limited
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Bausch Health Companies Inc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments